ELUT Elutia, Inc.
Mergers ·
The August 17, 2026 closing leaves the price open to an inventory adjustment and up to $3 million in contingent payments. Elutia says it will focus on NXT-41x and believes it has funding through the first full year of its commercial launch in 2028.
The sale closed October 1, 2025 for $88 million in cash, with $8 million held in escrow. Elutia used about $27.8 million to repay SWK Funding debt, and its 2024 annual report carried a going-concern warning after a net loss of $53.9 million.
Elutia sold its EluPro and CanGaroo bioenvelopes for cash. It plans to bring its NXT-41x breast reconstruction product to market in the first half of 2027.
Elutia receives no cash from the issuance. In its first-quarter results it said the change reduces cash outflows by $2.2 million in H1 2025.
Elutia develops proprietary drug-eluting biomatrix products for surgical reconstruction and related applications, aiming to reduce complications such as infection, migration, erosion, implant rejection and fibrosis. On October 1, 2025 it sold substantially all of the assets of its cardiac implantable electronic device business, including EluPro and CanGaroo, to Boston Scientific Corporation and Cardiac Pacemakers Inc. for an aggregate purchase price of up to $88.0 million in cash. It is now focused on its drug-eluting biomatrix platform. Its lead development programs are NXT-41, a next-generation biologic matrix, and NXT-41x, which adds local antibiotic delivery. Elutia continues to sell SimpliDerm, a human acellular dermal matrix, and its cardiovascular repair portfolio of ProxiCor, VasCure and Tyke through independent sales agents to healthcare facilities. Its headquarters and production space in Gaithersburg, Maryland supports development of NXT-41 and NXT-41x.
| Product or program | What it is | Stage |
|---|---|---|
| NXT-41 | Next-generation biologic matrix designed for consistent handling and scalable manufacturing | lead development program |
| NXT-41x | NXT-41 matrix with antibiotics released locally over extended periods | development; requires FDA marketing authorization |
| SimpliDerm | Human acellular dermal matrix used in soft tissue reconstruction | sold |
| ProxiCor | Cardiovascular repair product in the company’s Cardiovascular segment | sold |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $4.2 million | $3.0 million |
| Net income (loss) | $53.4 million | -$53.9 million |
| Cash from operations | -$44.8 million | -$22.7 million |
| Cash and equivalents | $36.4 million | $13.2 million |
Our latest story on this, dated Oct 7, 2025: "Elutia closes CIED business sale to Boston Scientific, puts $8 million in escrow, repays SWK loan". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 8, 2025: "Elutia issues 1,105,528 shares to Ligand to settle $2.2 million in royalties". The story links the filing or release it is based on. Read the story.
Elutia, Inc. trades under the ticker ELUT on NASDAQ.
Elutia, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Elutia, Inc. is 1708527. Its filings are on SEC EDGAR.
Our directory records Elutia, Inc. under United States.
Our directory classifies Elutia, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Elutia, Inc. is US05479K1060.
aibio.space lists Elutia, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Elutia develops proprietary drug-eluting biomatrix products for surgical reconstruction and related applications, aiming to reduce complications such as infection, migration, erosion, implant rejection and fibrosis. On October 1, 2025 it sold substantially all of the assets of its cardiac implantable electronic device business, including EluPro and CanGaroo, to Boston Scientific Corporation and Cardiac Pacemakers Inc. for an aggregate purchase price of up to $88.0 million in cash.
NXT-41: Next-generation biologic matrix designed for consistent handling and scalable manufacturing Stage: lead development program.
NXT-41x: NXT-41 matrix with antibiotics released locally over extended periods Stage: development; requires FDA marketing authorization.
Elutia, Inc. reported net income of $53.4 million for the fiscal year ended Dec 31, 2025, and used $44.8 million of cash in operations, per its annual report to the SEC.
$4.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio